纳米材料促进了对固体瘤的CAR-T疗法.
Jun Long1, Yian Wang2, Xianjie Jiang3
1Shenzhen Geim Graphene Center, Tsinghua-Berkeley Shenzhen Institute & Tsinghua Shenzhen International Graduate School, Tsinghua University, 1001 Xueyuan Road, Shenzhen, 518055, China.
Advanced healthcare materials
|March 14, 2024
概括
纳米材料可以通过提高特异性和降低成本来改善固体瘤的仿真抗原受体 (CAR) -T细胞疗法. 这种方法解决了CAR-T细胞生产和输送方面的挑战,以获得更好的癌症治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
- 材料科学 材料科学 材料科学
背景情况:
- 化学抗原受体 (CAR) -T细胞疗法在血液恶性瘤中显示出前景.
- 显著的挑战阻碍了CAR-T细胞在固体瘤中的有效性,包括抗原稀缺性,瘤微环境复杂性和制造限制.
- 目前的CAR-T细胞疗法面临着高成本和生产限制.
研究的目的:
- 审查纳米材料在CAR-T细胞治疗固体瘤中的应用.
- 探索纳米材料如何克服CAR-T细胞生产,向和输送方面的现有挑战.
- 评估纳米材料提高CAR-T细胞特异性,持久性和安全性的潜力.
主要方法:
- 关于纳米材料集成在CAR-T细胞治疗中的综合性文献综述.
- 分析纳米材料增强的CAR-T细胞功能背后的机制.
- 在CAR-T细胞基因改造和体内输送中对纳米材料应用的评估.
主要成果:
- 纳米材料可以降低CAR-T细胞生产中的变异性和成本.
- 纳米材料的整合可以增强CAR-T细胞的向性,持久性,并减少不良影响.
- 纳米材料为改善固体瘤中CAR-T细胞治疗提供了潜在的解决方案.
结论:
- 纳米材料集成是一个有前途的策略,可以推进对固体瘤的CAR-T细胞治疗.
- 对纳米材料应用的进一步研究可以提高CAR-T细胞的特异性,安全性和临床适用性.
- 用纳米材料解决制造和交付方面的挑战,可以扩大对有效的CAR-T细胞治疗的获取.
相关概念视频
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


